<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>CytoCares | wechat-feeds</title><link>http://MzAxNjQ3NjI4MA.favicon.privacyhide.com/favicon.ico</link><description>为您传递细胞治疗相关行业信息与技术进展，共同促进国内免疫治疗技术发展与行业繁荣。</description><managingEditor> (hellodword)</managingEditor><pubDate>Fri, 16 Apr 2021 19:20:02 +0800</pubDate><image><url>http://MzAxNjQ3NjI4MA.favicon.privacyhide.com/favicon.ico</url><title>CytoCares | wechat-feeds</title><link>http://MzAxNjQ3NjI4MA.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>双特异性抗体：on-target off-tumor毒性及克服策略</title><link>https://mp.weixin.qq.com/s/rfjJyKwyAzjLKggrsof_NQ</link><description></description><content:encoded><![CDATA[双特异性抗体：on-target off-tumor毒性及克服策略]]></content:encoded><pubDate>Fri, 16 Apr 2021 18:10:21 +0800</pubDate></item><item><title>抗体药物动态-20210416</title><link>https://mp.weixin.qq.com/s/yRFVHPDjzdOXp6v1KakixA</link><description></description><content:encoded><![CDATA[抗体药物动态-20210416]]></content:encoded><pubDate>Fri, 16 Apr 2021 18:10:21 +0800</pubDate></item><item><title>2021AACR年会：聚焦四大新型免疫疗法！CAR-T、TILs、癌症疫苗、溶瘤病毒大放异彩！</title><link>https://mp.weixin.qq.com/s/tQMmpoQtHfXXr49lTndJhg</link><description></description><content:encoded><![CDATA[2021AACR年会：聚焦四大新型免疫疗法！CAR-T、TILs、癌症疫苗、溶瘤病毒大放异彩！]]></content:encoded><pubDate>Thu, 15 Apr 2021 18:42:29 +0800</pubDate></item><item><title>罗氏新型Prot-2+1 TCB抗体</title><link>https://mp.weixin.qq.com/s/dPo1SaU3laJS0BqQzVzmQg</link><description></description><content:encoded><![CDATA[罗氏新型Prot-2+1 TCB抗体]]></content:encoded><pubDate>Wed, 14 Apr 2021 18:23:11 +0800</pubDate></item><item><title>抗体药物动态-20210414</title><link>https://mp.weixin.qq.com/s/-omuvyguHryOCbWpicjCKQ</link><description></description><content:encoded><![CDATA[抗体药物动态-20210414]]></content:encoded><pubDate>Wed, 14 Apr 2021 18:23:11 +0800</pubDate></item><item><title>IL-22与炎症性疾病</title><link>https://mp.weixin.qq.com/s/2RlnI0e_cyb1DUCd2c9R6Q</link><description></description><content:encoded><![CDATA[IL-22与炎症性疾病]]></content:encoded><pubDate>Tue, 13 Apr 2021 18:59:52 +0800</pubDate></item><item><title>抗体药物动态-20210413</title><link>https://mp.weixin.qq.com/s/JxGPf-C6HB0n0BvSbKDOmQ</link><description></description><content:encoded><![CDATA[抗体药物动态-20210413]]></content:encoded><pubDate>Tue, 13 Apr 2021 18:59:52 +0800</pubDate></item><item><title>ALL和NHL领域，临床开发中的双特异抗体</title><link>https://mp.weixin.qq.com/s/M0kLH4_rG0IMpvf9IrmVfQ</link><description></description><content:encoded><![CDATA[ALL和NHL领域，临床开发中的双特异抗体]]></content:encoded><pubDate>Mon, 12 Apr 2021 18:46:46 +0800</pubDate></item><item><title>抗体药物动态-20210412</title><link>https://mp.weixin.qq.com/s/VaiKS8ycrueyyX0rQo8amA</link><description></description><content:encoded><![CDATA[抗体药物动态-20210412]]></content:encoded><pubDate>Mon, 12 Apr 2021 18:46:46 +0800</pubDate></item><item><title>TIGIT+记忆B细胞在免疫调节中的作用</title><link>https://mp.weixin.qq.com/s/ojkM_fL6WYq2Hfqa5KwFDw</link><description></description><content:encoded><![CDATA[TIGIT+记忆B细胞在免疫调节中的作用]]></content:encoded><pubDate>Wed, 07 Apr 2021 19:03:47 +0800</pubDate></item><item><title>抗体药物动态-20210407</title><link>https://mp.weixin.qq.com/s/Ca7bpEJCk1w0IDPsp7Q4CQ</link><description></description><content:encoded><![CDATA[抗体药物动态-20210407]]></content:encoded><pubDate>Wed, 07 Apr 2021 19:03:47 +0800</pubDate></item><item><title>TG-Bio第二届免疫治疗技术大会开幕在即，聚焦细胞/基因治疗！</title><link>https://mp.weixin.qq.com/s/PHdd3N-0SilqN6AM1jF9mg</link><description></description><content:encoded><![CDATA[TG-Bio第二届免疫治疗技术大会开幕在即，聚焦细胞/基因治疗！]]></content:encoded><pubDate>Wed, 07 Apr 2021 19:03:47 +0800</pubDate></item><item><title>全球第五款上市的CAR-T药物：靶向BCMA</title><link>https://mp.weixin.qq.com/s/kLDNZ694Y60EChTgGk6Uig</link><description></description><content:encoded><![CDATA[全球第五款上市的CAR-T药物：靶向BCMA]]></content:encoded><pubDate>Tue, 06 Apr 2021 18:57:05 +0800</pubDate></item><item><title>抗体药物动态-20210406</title><link>https://mp.weixin.qq.com/s/rZCt662Xa3a6Gj3fk28GWg</link><description></description><content:encoded><![CDATA[抗体药物动态-20210406]]></content:encoded><pubDate>Tue, 06 Apr 2021 18:57:05 +0800</pubDate></item><item><title>ADCC效应强于IgG，IgA成药难点和工程改造!</title><link>https://mp.weixin.qq.com/s/loS6bFoYEKFZwlifeVVVfQ</link><description></description><content:encoded><![CDATA[ADCC效应强于IgG，IgA成药难点和工程改造!]]></content:encoded><pubDate>Tue, 30 Mar 2021 18:46:05 +0800</pubDate></item><item><title>抗体药物动态-20210330</title><link>https://mp.weixin.qq.com/s/iIzTJBECqpdwmNty_PHUOQ</link><description></description><content:encoded><![CDATA[抗体药物动态-20210330]]></content:encoded><pubDate>Tue, 30 Mar 2021 18:46:05 +0800</pubDate></item><item><title>帮助Moderna开发mRNA疫苗的背后，Ginkgo正在探索加帽酶的规模生产</title><link>https://mp.weixin.qq.com/s/L4YeysqIBkiU1xeCVSSh5g</link><description></description><content:encoded><![CDATA[帮助Moderna开发mRNA疫苗的背后，Ginkgo正在探索加帽酶的规模生产]]></content:encoded><pubDate>Mon, 29 Mar 2021 18:23:51 +0800</pubDate></item><item><title>抗体药物动态-20210329</title><link>https://mp.weixin.qq.com/s/QgkuFIGpjKSpScNcE5hQng</link><description></description><content:encoded><![CDATA[抗体药物动态-20210329]]></content:encoded><pubDate>Mon, 29 Mar 2021 18:23:51 +0800</pubDate></item><item><title>肿瘤治疗新秀：mRNA疫苗</title><link>https://mp.weixin.qq.com/s/3lyfNWIpRLrmoWcLc5SaqA</link><description></description><content:encoded><![CDATA[肿瘤治疗新秀：mRNA疫苗]]></content:encoded><pubDate>Fri, 26 Mar 2021 18:53:43 +0800</pubDate></item><item><title>抗体药物动态-20210326</title><link>https://mp.weixin.qq.com/s/ckcZ5SDsyX8NJVK40WczuA</link><description></description><content:encoded><![CDATA[抗体药物动态-20210326]]></content:encoded><pubDate>Fri, 26 Mar 2021 18:53:43 +0800</pubDate></item></channel></rss>